Dyne Therapeutics Announces Key Leadership Appointments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro softer after ECB stands pat on rates
Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)
September 3, 2024 11:45 AM EDTOppenheimer analyst Francois Brisebois reiterated an Outperform rating and $55.00 price target on Dyne Therapeutics (NASDAQ: DYN).
The analyst comments "DYN reported new clinical data from its P1/2 DYNE-251 for DMD dose optimization studies. In addition to dose-dependent PMO delivery to muscle and exon... More
